Get started
MarketMoversReport

FDA Grants Orphan Drug Designation for BioCryst’s ALK2 Inhibitor

Long
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)  
MarketMoversReport  
NASDAQ:BCRX   BioCryst Pharmaceuticals, Inc.
Beyond Technical Analysis
0
0
beyondta
BCRX: BioCryst Pharmaceuticals, Inc.
2022-08-31 07:00:00 FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.